New research indicates that people who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise programs.
Research printed in a major health publication shows that while obese people frequently drop about a fifth of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month after stopping.
"People buying these medications need to be aware of the danger of quick weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
This pace of regain means a return to starting weight within about a year and a half.
Analyzing Therapies
The study, which examined dozens of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with conventional dieting.
Researchers emphasize that individuals who shed pounds through dieting generally experience a more gradual weight regain—around 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Nutrition scientists suggest the mechanism of the jabs is key to understanding the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in hunger is uncontrolled, making overeating far more likely."
A Chronic Disease?
Health authorities advise the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, due to the significant potential of weight regain, the treatment might need to be ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "underscore the persistent character of excess weight," comparing it to managing diseases like diabetes.
Patient Experiences
Individuals who have discontinued the jabs describe a sudden return of cravings.
"I experienced a trigger that goes on and you become ravenous," recalled a patient.
This challenge is compounded if users have not established lasting lifestyle or habit changes during treatment.
Widespread Adoption
Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is higher among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are potent agents for weight loss, they are not a magic solution and maintained weight loss hinges on integrated behavioural support.
